Dylan Williams
@dylan_wi11iams
Followers
422
Following
289
Statuses
903
Molecular epidemiologist investigating neurodegenerative & cerebrovascular diseases. Principal research fellow at UCL's @MRCLHA
London
Joined April 2010
Delighted to start as a Senior Fellow for @AlzResearchUK this month! As are my two chief mascots (help from Bluey here to keep them still). My research will look for ways to combat the bad effects of a protein called apoE, which is the predominant cause of Alzheimer's disease
2
0
19
@AlzResearchUK ...thanks so much to my sponsors, collaborators, colleagues and reviewing scientists and board at ARUK for the support / trust in me to do this work
0
0
2
RT @davidabann: New preprint: genetic liability + BMI across generations born 1946, 1958, 1970, 2001. Led by Liam Wright @clscohorts @MRCL…
0
5
0
@BBCBreaking @BBCFergusWalsh your stat on APOE e4/e4 carriage in this article is very wrong. In European populations, the proportion with e4/e4 is ~2.5%
1
0
1
@jbrain12 @SheaJAndrews But it is wrong to view genetic risk as unmodifiable, either literally (gene editing, silencing, therapies) or in downstream terms by intervening on proteins that genes encode (the basis of almost all pharmacology)
1
0
0
@emmylooroll @SheaJAndrews Agree with you both ... I told a journo on Mon that this is one of the biggest problems with the new report (plus worries about causality for their 14 factors)
0
0
2
Excited to see more focus on APOE in meetings mentioned by @JefferyMVance at #AAIC24, inc this one by @NIHAging in Sept. I have fixed the incorrect article in its title though
0
1
6
RT @Caterina_Felici: If you fancy learning more about infections and their link with amyloid pathology, stop by Poster 693 today at #AAIC20…
0
2
0
@pitchfork @LosCampesinos I can't believe you finally got one of these .... 17 years overdue IMO
0
0
0
Launching a new in-person short course on Mendelian randomisation for students, ECRs/MCRs/SCRs, professionals this autumn at UCL with the fantastic @emmylooroll @nm_davies. Details in thread below. Hope to see you in Bloomsbury this September!
🧬Join us for a 3-day in-person course on Mendelian randomisation at UCL from 24th-26th September. This course introduces some of the theory and most widely used tools for MR, and how to apply these methods to real research questions.
0
7
13
@gushamilton @emmylooroll I meant pervasive sharing beyond registered users & registered uses. Ultimately, provisioning local data is trust-based, easily abused & undermined through incompetence. TREs are a good alternative WRT this but UKB's solution has several drawbacks that academic TREs do not IME
2
0
1
@emmylooroll I've heard that the downloading of the cohort's data has been badly abused at times, particularly in some territories
1
0
1
@emmylooroll @uk_biobank @DementiasUK @ourfuturehealth I suppose the issue is while DPUK, UK LLC and presumably Our Future Health are using TREs from academic partners (SeRP) for the former two, UKB's service is from a commercial vendor wringing 'em for £££
1
0
1
@don_sci Minor point ... I agree with John's first statement of course, but I wonder if we stop saying things like "determinant of risk" about apoE & be more direct about cause. To people without good understanding of multifactorial disease it gives impression of peripheral involvement
0
0
0
@lcpilling as per Rose 'Sick individuals, Sick populations'; Lewontin 1974 PMID: 4827368; Bjork 2019 doi 10.1007/s10654-019-00573-8; Robette 2022 doi 10.1007/s10709-022-00149-7
0
0
1
RT @UKLLCollab: 📢NEW PUBLICATION using data held in UK LLC's TRE is out in The Lancet: Dylan Williams and his team…
0
8
0